Dr Sam Goldhaber catches up with Dr Stavros Konstantinides for a comprehensive review ofthe important trials on PE thrombolysis and a discussion of what direction future research will take.
See also:
MAPPET 1 registry of "major" PE:
Kasper W, Konstantinides S, Geibel A. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997;30:1165-1171. Available here.
Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 1997; 96:882-8. Available here.
MAPPET 2 cohort study on biomarkers in PE:
Konstantinides S, Geibel A, Olschewski M, et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002; 106:1263-8. Available here.
MAPPET-3 trial:
Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347:1143-50. Available here.
Stein PD, Matta F, Steinberger DS, et al. Intracerebral hemorrage with thrombolytic therapy for acute pulmonary embolism. Am J Med 2012; 125:50-56. Abstract.
Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: Saves lives but underused. Am J Med 2012; 125:465-470. Abstract.
All about Pulmonary Embolism: Assessing Risk, Managing Patients
Cite this: Recent PE thrombolysis trials: MAPPET, MOPETT, and MUPPET, with Dr Stavros Konstantinides - Medscape - Apr 27, 2012.
Comments